UK In Major Move To Boost Commercial Clinical Trials & Improve Life Sciences Environment
The publication of two major reports has led the UK government to announce a £650m “Life Sci for Growth” package to bolster the life sciences sector.
You may also be interested in...
A panel of experts has outlined several areas for improvement in the UK’s life sciences ecosystem in light of a report by Sanofi that supports claims that the UK is lagging behind EU competitors in its delivery of innovative medicines to patients.
The UK government has set aside dedicated funds to deliver ambitious changes that would make it quicker and easier for companies to trial more of their products in the National Health Service.
The body representing generics and biosimilars companies in the UK is seeking a seat at the table as negotiations on a new voluntary price scheme get under way.